<DOC>
	<DOCNO>NCT02052596</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , reactogenicity safety GSK Biologicals ' HZ/su vaccine first dose co-administered Boostrix® vaccine adult age 50 year old compare administration vaccine separately .</brief_summary>
	<brief_title>Study Assess Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine ( GSK1437173A ) When Co-administered With GSK Biologicals ' Diphtheria , Tetanus Pertussis Vaccine ( Boostrix® ) Adults Aged 50 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female age 50 year old time first vaccination study vaccine ( ) . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose ( corticosteroid , mean prednisone ≥ 20 mg/day , equivalent ) . A prednisone dose &lt; 20 mg/day allow . Inhaled , topical intraarticular corticosteroid allow . Administration plan administration vaccine foreseen study protocol within period start 30 day first dose study vaccine ( ) end 30 day last dose study vaccine . This include type vaccine ( limited ) live , inactivated subunit vaccine ( e.g. , inactivate subunit influenza vaccine ) . Administration longacting immunemodifying drug ( e.g . infliximab ) within six month prior first vaccine dose expect administration time study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Previous vaccination VZV HZ and/or plan administration study HZ VZV vaccine ( include investigational nonregistered vaccine ) study vaccine . History HZ . Vaccination diphtheria , tetanus last five year plan vaccination diphtheria tetanus study period , study vaccine ( ) . Administration combine tetanus , diphtheria pertussis ( Tdap ) vaccine time prior study entry . Any confirm suspected immunosuppressive immunodeficient condition result disease ( e.g. , malignancy , human immunodeficiency virus [ HIV ] infection ) immunosuppressive/cytotoxic therapy ( e.g. , medication use cancer chemotherapy , organ transplantation treat autoimmune disorder ) . History reaction hypersensitivity likely exacerbate component vaccine include prior severe allergic reaction follow tetanustoxoid , diphtheriatoxoid pertussiscontaining vaccine . Hypersensitivity latex . Note : The investigational HZ/su vaccine contain latex . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 2 month last dose study vaccine . Any condition , opinion investigator , prevents subject participate study . Any condition , judgment investigator , would make intramuscular ( IM ) injection unsafe . Encephalopathy ( e.g . coma , decrease consciousness , prolonged seizure ) attributable identifiable cause within 7 day administration previous pertussis antigencontaining vaccine . Progressive unstable neurologic disorder . History Arthustype hypersensitivity reaction follow prior dose tetanustoxoid contain vaccine within last 10 year . History GuillainBarré syndrome within 6 week receipt prior vaccine contain tetanus toxoid .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Boostrix</keyword>
	<keyword>Herpes zoster</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Co-administration</keyword>
	<keyword>Adults</keyword>
	<keyword>Safety</keyword>
</DOC>